Ocugen, Inc. (OCGN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Research, Development and Commercialization of its Novel Gene Therapies	4.05M	6.04M	2.49M	-	43.00K
Research, Development and Commercialization of its Novel Gene Therapies Growth	-32.82%	142.60%	-	-	-
Total	4.05M	6.04M	2.49M	-	43.00K
Total Growth	-32.82%	142.60%	-	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
United States	4.05M	6.04M	2.49M	-	43.00K
United States Growth	-32.82%	142.60%	-	-	-
Total	4.05M	6.04M	2.49M	-	43.00K
Total Growth	-32.82%	142.60%	-	-	-

Source: S&P Global Market Intelligence.